35K-25783-54677
3 vaccinations
3 coded responses
23 check-ins
3 free-text entries
1 call case
- Sex
- Female
- Age at first dose
- 31-35
- ZIP prefix
- 724 / AR
- Registered
- 2021-03-03
- Relationship
- Self
- Race
- White
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2021-02-25
Dose 1 — Moderna
-
2021-03-03
Registered in v-safe
-
2021-03-03
Survey response — days 1–6 daily, dose 1MedDRA: No adverse event — Feeling: Good · Site: Pain, Redness, Itching · Headache, Muscle or body aches, Fatigue or tirednessFree text: NoneMedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
- 2021-03-04
- 2021-03-11
- 2021-03-18
-
2021-03-25
Dose 2 — Moderna
-
2021-03-25
Health check-in — day 0, dose 2Feeling: Poor · Site: Pain, Redness · Fever · Chills, Headache, Muscle or body aches, Fatigue or tiredness, Nausea, Diarrhea · Be unable to do your normal daily activitiesAdult check-in
-
2021-03-26
Health check-in — days 1–6 daily, dose 2Feeling: Poor · Site: Pain, Itching · Fever · Chills, Headache, Joint pains, Muscle or body aches, Fatigue or tiredness, Nausea · Be unable to do your normal daily activitiesAdult check-in
- 2021-03-27
-
2021-03-28
Health check-in — days 1–6 daily, dose 2Feeling: Good · Site: Pain · Joint pains, Diarrhea, Abdominal painAdult check-in
- 2021-03-29
- 2021-03-30
- 2021-03-31
- 2021-04-01
- 2021-04-08
- 2021-04-15
- 2021-04-22
- 2021-04-29
- 2021-05-06
- 2021-06-24
- 2021-09-23
-
2022-01-27
Dose 3 — Pfizer-BioNTech
-
2022-03-25
Survey response — 12 months, dose 2MedDRA: Pityriasis rosea, Rash — Feeling: Good · Get care from a doctor or other healthcare professional · Outpatient clinic or urgent care clinic visitFree text: Skin rash - pytiriasis roseaMedDRA releases: 2024-11 · check-in free text available
-
2022-03-25
Report sent to call center — 12 months, dose 2Get care from a doctor or other healthcare professionalOutpatient clinic or urgent care clinic visit · 1 call case(s)
- 2022-03-28
- 2022-04-28
-
2022-07-28
Survey response — 6 months, dose 3MedDRA: Arthralgia, COVID-19, Dyspnoea, Fatigue, Increased viscosity of upper respiratory secretion, Myalgia, Pregnancy, Respiratory tract congestion — Feeling: Good · Be unable to work or attend school, Be unable to do your normal daily activitiesFree text: Had covid 2 wks ago- sx lasted 4-5 days: myalgias, arthralgias, fatigue, congestion, mild dyspnea, thick mucus secretions. I am also pregnant.MedDRA releases: 2024-11 · check-in free text available
- 2023-01-29
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2021-02-25 | Moderna | |
| 2 | 2021-03-25 | Moderna | |
| 3 | 2022-01-27 | Pfizer-BioNTech | No |
Call center
| Reported | Outcome | VAERS-related outcome |
|---|---|---|
| 2022-03-25 | Unsuccessful |
Free text
Release 5 — days 1–6 daily, dose 1
Systemic reaction (other): None
Release 11 — 12 months, dose 2
Symptoms: Skin rash - pytiriasis rosea
Release 12 — 6 months, dose 3
Symptoms: Had covid 2 wks ago- sx lasted 4-5 days: myalgias, arthralgias, fatigue, congestion, mild dyspnea, thick mucus secretions. I am also pregnant.
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SD | Arthralgia | · | · | ✓ |
| SD | COVID-19 | · | · | ✓ |
| SD | Dyspnoea | · | · | ✓ |
| SD | Fatigue | · | · | ✓ |
| SD | Increased viscosity of upper respiratory secretion | · | · | ✓ |
| SD | Myalgia | · | · | ✓ |
| SD | Pityriasis rosea | · | · | ✓ |
| SD | Pregnancy | · | · | ✓ |
| SD | Rash | · | · | ✓ |
| SD | Respiratory tract congestion | · | · | ✓ |
| SRO | No adverse event | ✓ | ✓ | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release